Ashvattha Therapeutics Presents Promising Preclinical Data on New Dendranib Nanomedicine Candidate ASH41020 at the 16th International Society of Neuroimmunology Congress (ISNI)
Data demonstrated that ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, directs macrophage polarization toward the anti-inflammatory M2 phenotype ASH41020 treatment lessened disease severity in a preclinical model of multiple sclerosis (MS) to a similar extent to fingolimod, an approved MS treatment Study suggests ASH41020 is a potent anti-inflammatory and immunomodulatory agent that warrants further … Read more